Edesa Biotech, Inc. — Form 10-Q Summary
Reporting period: Fiscal third quarter and nine months ended June 30, 2022; the filing was signed August 12, 2022. Edesa is a clinical-stage biopharmaceutical company developing treatments for inflammatory and immune-related diseases. It reported no significant revenue and continues to fund operations through equity financing, government grants and other sources.
Key financial metrics
| Metric | Three months ended June 30, 2022 | Nine months ended June 30, 2022 |
|---|---|---|
| Research and development expense | $4.55 million | $11.54 million |
| General and administrative expense | $1.25 million | $3.99 million |
| Operating loss | $5.80 million | $15.53 million |
| Net loss | $5.79 million ($0.37 per share) | $14.74 million ($1.04 per share) |
- Cash and liquidity: Cash and cash equivalents were $12.81 million at June 30, 2022, up from $7.84 million at September 30, 2021. Working capital was $9.52 million.
- Cash flow: Operating activities used $6.65 million in the nine months, compared with $13.31 million in the prior-year period. Financing provided $11.63 million, primarily from equity issuance. Investing used $0.006 million.
- Balance sheet: Total assets were $17.54 million, total liabilities $5.70 million and shareholders’ equity $11.84 million. The filing reports lease liabilities and long-term payables but no significant borrowings.
- Margins: The filing provides no meaningful margin measure; Edesa is clinical-stage and reported no significant revenue.
Changes versus prior comparable periods
- Quarterly operating expenses declined $0.27 million year over year, while net loss increased from $4.76 million to $5.79 million. Reimbursement grant income fell from $1.31 million to zero for the quarter, more than offsetting the lower operating expenses.
- Nine-month operating expenses declined $2.67 million year over year, but net loss increased from $9.66 million to $14.74 million. Grant income dropped from $8.48 million to $0.78 million.
- Cash increased during the nine-month period, supported by approximately $11.63 million of net financing cash flow. The March 2022 registered direct offering and concurrent warrant placement generated approximately $9.01 million net; the ATM program generated approximately $2.62 million net before its termination in March.
- Common shares outstanding increased from 13.30 million at September 30, 2021 to 15.46 million at June 30, 2022. The company also had 3.65 million common warrants and 1.20 million pre-funded warrants outstanding at June 30.
Outlook, risks and commitments
- Management planned to fund operations over the next 12 months with cash on hand and eligible Canadian Strategic Innovation Fund reimbursements. It also said it expects to seek additional financing; adequate funding on acceptable terms is not assured.
- For EB01, management anticipated completing enrollment of 210 participants in the Phase 2b chronic allergic contact dermatitis study in the fourth calendar quarter of 2022, with preliminary topline data as early as the first quarter of 2023.
- For EB05, enrollment was underway in parallel cohorts for critically ill hospitalized COVID-19 patients: patients receiving mechanical ventilation plus additional organ support and patients receiving invasive ventilation alone. The latter cohort protocol calls for approximately 500 evaluable subjects. The company anticipated submitting a Phase 2 clinical study report to the FDA in the third calendar quarter of 2022 to support review of the Phase 3 design.
- Management cited ongoing uncertainty from COVID-19, clinical-study timing and funding availability. Clinical expenses may fluctuate with study initiation and patient recruitment.
- Contracted research and other service commitments totaled $3.28 million at June 30, 2022. Separate license agreements include contingent future milestone payments of up to $352.5 million and $68.9 million, as well as other potential milestone and royalty obligations; these are contingent, not current debt.
- The filing reports no material changes to the risk factors in the prior Form 10-K and no material legal proceedings outside the ordinary course. Disclosure controls were assessed as effective, with no material internal-control changes reported during the quarter.
Important facts for investors to verify
- Whether cash, grant reimbursements and spending plans remain sufficient as clinical trials progress, and when additional financing may be needed.
- Enrollment, regulatory review and readout timing for the EB05 and EB01 clinical programs, including the FDA’s review of EB05’s study design.
- The remaining availability and collection timing of Strategic Innovation Fund reimbursements, given the substantial year-over-year reduction in grant income.
- Potential dilution from outstanding warrants, pre-funded warrants, options and future equity financing.
- The conditions, timing and potential scale of contingent license milestones and royalties.